Scion Life Sciences Welcomes New Venture Partners to Boost Biotechnology Innovation

Scion Life Sciences Welcomes New Venture Partners

Scion Life Sciences, a venture capital firm committed to developing transformative biotechnology companies, has made a move to expand its operational capacity with the appointment of three prominent figures in the industry. On April 17, 2025, the firm announced that it has brought on board Lalo Flores, Ph.D., Huw Nash, Ph.D., and Romesh Subramanian, Ph.D. as Venture Partners. Their expertise is expected to significantly enhance Scion's capabilities and lead the growth of three undisclosed portfolio companies.

Elevating Leadership

The addition of these three seasoned professionals is crucial as Scion embarks on an ambitious journey to accelerate the development of its first set of portfolio companies. According to Samuel Hall, Co-Founder and Managing Partner of Scion Life Sciences, ‘We are thrilled to welcome Lalo, Huw, and Romesh to the Scion family. All three are exceptional leaders, innovators, and builders with proven track records of building great companies and embody Scion's science-forward approach to company-building and dedication to therapeutic innovation with clinically transformational or curative potential.’

Each new partner brings a wealth of experience that is not only valuable to the respective portfolio companies but also aligns with Scion’s overarching mission to pioneer solutions that meaningfully improve human health. This multi-faceted expertise will allow Scion to better support the operational needs of its portfolio investments during critical phases of growth.

Diverse Experiences for Diverse Outcomes

Lalo Flores, Ph.D., with over 30 years in the biopharmaceutical sphere, has a notable history that includes pivotal roles at Tularik, Merck, and Johnson & Johnson. He co-founded Novira Therapeutics, which was acquired in 2015, and has also served as the CEO of Century Therapeutics, making it public in 2021. Through his insights, Flores aims to significantly contribute to Scion's hands-on company-building ethos. “Scion's approach is an excellent platform for sharing my experience. I look forward to leveraging it as we foster innovative biotech companies,” he remarked.

Huw Nash, Ph.D., brings over 25 years of experience in both entrepreneurial and operational capacities. Before joining Scion, he played a crucial role at Stoke Therapeutics and contributed to its evolution from concept to NASDAQ listed company. Nash emphasized his enthusiasm for partnering with Scion once again, expressing excitement about building transformative biotech firms that can impact healthcare.

Similarly, Romesh Subramanian, Ph.D., provides a strong foundation in both academic and executive environments with his history of developing RNA-targeted medicines at Ascidian Therapeutics and essential leadership at Dyne Therapeutics. With expertise in mRNA and antibody therapeutics, he is poised to leverage well-validated modalities to drive innovation within Scion's portfolio. “It’s an honor to join such a dynamic team at Scion,” Subramanian stated.

Growing Financial Commitment

Scion Life Sciences currently has over $140 million secured through funding to kickstart its first wave of portfolio companies. The firm aims to unlock even more capital in the coming 12-18 months as these startups reach significant development milestones. This investment strategy signposts a robust commitment to not only grow its companies but also contribute positively to healthcare advancements.

With the announcements surrounding the new venture partners, expectations are high as Scion prepares to disclose further details about its expanding portfolio. The firm is drawn to therapeutic innovations that promise to transform clinical outcomes and improve quality of life for patients.

About Scion Life Sciences

Scion Life Sciences stands at the forefront of venture capital, dedicated to cultivating exceptional biotechnology firms aimed at discovering, developing, and commercializing clinically transformative therapies. Through strategic ownership, the firm endeavors to make meaningful contributions towards enhancing public health and fostering groundbreaking innovations. Their mission is not just to invest but to create a sustainable ecosystem geared towards impactful advancements in healthcare.

For more insights into Scion's transformative journey and the new partners’ contributions, stay tuned for their upcoming announcements.